Skip to main content
. Author manuscript; available in PMC: 2020 Jun 2.
Published in final edited form as: Sex Transm Infect. 2019 Mar 14;95(7):511–515. doi: 10.1136/sextrans-2018-053824

Table 2.

Rate of Sexual Activitiesβ and Douching per 100 Days of Follow-Up (95% CI), Adjusting for Age Group

Sexual Activity or Symptoms Incident BV n=14 No Incident BV N=22 Relative Incidence p-value*
Any sexual activity 20.4 (16.4–25.5) 14.6 (12.8–16.6) 1.40 (1.08–1.81) 0.010
Sex with a woman 14.3 (11.0–18.5) 10.3 (8.9–12.0) 1.38 (1.02–1.87) 0.038
Sex with a man 3.4 (2.0–5.86) 2.8 (2.0–3.8) 1.23 (0.66–2.28) 0.511
Sex with a new female partner 0.5 (0.2–1.38) 0 - -
Sex with a new male partner 1.3 (0.3–5.4) 0.4 (0.2–0.8) 3.71 (0.62–22.20) 0.151
Receptive oral sex 8.1 (5.7–11.4) 9.2 (7.8–10.8) 0.88 (0.60–1.29) 0.515
Direct genital-genital contact 3.9 (2.3–6.4) 5.3 (4.2–6.5) 0.73 (0.42–1.28) 0.277
Sex toy use 3.5 (2.1–6.0) 3.0 (2.3–4.0) 1.17 (0.64–2.16) 0.605
Inconsistent dental dam use 14.2 (11.0–18.5) 11.3 (9.7–13.1) 1.26 (0.93–1.71) 0.132
Inconsistent condom use 2.1 (0.9–5.3) 1.3 (0.8–2.0) 1.65 (0.59–4.63) 0.343
Any digital-vaginal sex 14.3 (11.0–18.7) 9.1 (7.8–10.7) 1.57 (1.15–2.15) 0.005
Any digital-anal sex 2.9 (1.6–5.3) 0.5 (0.3–1.0) 5.56 (2.4–12.8) <0.001
Any finger or hand on vagina 16.6 (13.0–21.1) 12.4 (10.8–14.3) 1.33 (1.00–1.77) 0.048
Douching** 0 0.2 (0.1–0.7) - -
BV Symptoms 3.4 (1.9–6.3) 12.5 (10.9–14.3) 0.27 (0.15–0.51) <0.001
β

Sex with a female or male partner was defined as any oral, vaginal, and/or anal sexual contact. Direct genital-genital contact refers to the genital regions of each partner touching during sex (could be between two female sexual partners or female-male sexual partners). Sex toy use could include shared use however this data was not specifically captured. Data on vaginal insertion of sex toys or external use only was also not captured.

*

p-values calculated from a Poisson model adjusting for age group (<30, ≥30 years)

There were 428 days of follow-up in the incident BV group (mean, 30.6 days) and 1614 days of follow-up in the non-incident BV group (mean, 73.4 days).

**

Unadjusted estimates presented since the age-adjusted model would not converge.